Literature DB >> 17094994

Statin-associated adverse effects beyond muscle and liver toxicity.

D N Kiortsis1, T D Filippatos, D P Mikhailidis, M S Elisaf, E N Liberopoulos.   

Abstract

Randomized controlled trials with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have consistently demonstrated significant reductions in cardiovascular morbidity and mortality. Statins are currently the most widely used drugs in many countries. The most important adverse effects are associated with muscle and liver toxicity. However, with increased use and dose of statins and their over-the-counter availability in some countries more cases of other rare side effects may be seen in clinical practice. In the present article we review the literature concerning the statin-related adverse effects other than muscle and liver injury and we provide insight into their clinical relevance and possible underlying mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094994     DOI: 10.1016/j.atherosclerosis.2006.10.001

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  21 in total

1.  Two cases of statin-induced rhabdomyolysis associated with mononeuropathy.

Authors:  Gian Paolo Fadini; Enzo Manzato; Cristina Crepaldi; Saula de Kreutzenberg; Antonio Tiengo; Angelo Avogaro
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses.

Authors:  Ioana Smith; Robert Schmidt; Ethan A Halm; Ishak A Mansi
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 3.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

4.  Pharmacokinetics, metabolism, bioavailability, tissue distribution and excretion studies of 16α-hydroxycleroda-3, 13(14) Z -dien-15, 16-olide-a novel HMG-CoA reductase inhibitor.

Authors:  Tulsankar Sachin Laxman; Santosh Kumar Puttrevu; Rajesh Pradhan; Anjali Mishra; Sarvesh Verma; Yashpal S Chhonker; Swarnim Srivastava; Suriya P Singh; Koneni V Sashidhara; Rabi Sankar Bhatta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-06       Impact factor: 3.000

5.  Aryl hydrocarbon receptor regulates the cholesterol biosynthetic pathway in a dioxin response element-independent manner.

Authors:  Rachel Tanos; Rushang D Patel; Iain A Murray; Philip B Smith; Andrew D Patterson; Gary H Perdew
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

Review 6.  Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis.

Authors:  Eun Ji Chung; Matthew Tirrell
Journal:  Adv Healthc Mater       Date:  2015-06-17       Impact factor: 9.933

7.  Inhibitory effects of simvastatin on staphylococcus aureus lipoteichoic acid-induced inflammation in human alveolar macrophages.

Authors:  Ben-Quan Wu; Jin-Mei Luo; Yan-Hong Wang; Yun-Feng Shi; Hui Liu; Jun-Hui Ba; Tian-Tuo Zhang
Journal:  Clin Exp Med       Date:  2013-03-03       Impact factor: 3.984

8.  Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.

Authors:  Nicholas Theodosakis; Casey G Langdon; Goran Micevic; Irina Krykbaeva; Robert E Means; David F Stern; Marcus W Bosenberg
Journal:  Pigment Cell Melanoma Res       Date:  2018-10-22       Impact factor: 4.693

9.  Statin use and cataract surgery: a nationwide retrospective cohort study in elderly ethnic Chinese patients.

Authors:  Chao-Lun Lai; Wen-Yi Shau; Chia-Hsuin Chang; Ming-Fong Chen; Mei-Shu Lai
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

10.  Accounting for clinical action reduces estimates of gender disparities in lipid management for diabetic veterans.

Authors:  Varsha G Vimalananda; Donald R Miller; Timothy P Hofer; Robert G Holleman; Mandi L Klamerus; Eve A Kerr
Journal:  J Gen Intern Med       Date:  2013-07       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.